DEFM14A: Alumis to Acquire ACELYRIN in All-Stock Merger, Creating Combined Biopharmaceutical Powerhouse

Alumis and ACELYRIN have agreed to merge in an all-stock transaction, aiming to create a leading biopharmaceutical company with a diversified pipeline.

Summary

• Alumis and ACELYRIN have entered into a definitive merger agreement where Alumis will acquire ACELYRIN in an all-stock transaction.
• Under the terms of the agreement, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own.
• Following the merger, Alumis stockholders are expected to own approximately 55% and ACELYRIN stockholders approximately 45% of the combined company.
• The merger aims to create a stronger biopharmaceutical company with a diversified pipeline and extended cash runway.
• Both Alumis and ACELYRIN will hold virtual special meetings on May 13, 2025, for their respective stockholders to vote on the merger-related proposals.
• The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.
• The combined company will focus on developing treatments for immune-mediated diseases.
• The completion of the Merger is not subject to any financing condition.

Sentiment

Score: 7

Explanation: The document is largely factual and descriptive, with a moderately positive outlook regarding the potential benefits of the merger. However, it also includes cautionary language about risks and uncertainties.

Positives

• The merger creates a well-capitalized company with a cash runway into 2027.
• The combined company will have a diversified pipeline of product candidates.
• The merger is expected to generate operating efficiencies and cost savings.
• ACELYRIN stockholders have the opportunity to participate in the potential value creation of the combined company.
• The merger is supported by voting agreements from key stockholders of both companies.

Negatives

• The Exchange Ratio is fixed and will not be adjusted based on the market price of Alumis common stock, so the consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.
• Current Alumis stockholders will have a reduced ownership interest and voting power in the combined company after the Merger.
• The combined company may fail to realize the anticipated benefits of the Merger.

Risks

• The merger may not be completed on the terms or timeline currently contemplated, or at all.
• The pendency of the merger could adversely affect the business and operations of Alumis and ACELYRIN.
• The combined company may fail to realize the anticipated benefits of the merger.
• Failure to attract, motivate and retain executives and other key employees could diminish the anticipated benefits of the Merger.
• If the combined company is unable to compete effectively, the results of operations of the combined company will be materially and adversely affected.

Future Outlook

The combined company will focus on advancing a diversified pipeline of product candidates and expects multiple development milestones in 2025 and 2026.

Management Comments

• Alumis and ACELYRIN encourage you to read this entire joint proxy statement/prospectus carefully, including the section titled Risk Factors beginning on page 35 of this joint proxy statement/prospectus.
• We look forward to the successful Merger of Alumis and ACELYRIN.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to diversify risk and enhance pipeline depth.

Comparison to Industry Standards

• The document does not provide specific details on how the merger compares to industry standards in terms of valuation multiples or deal structures.
• It mentions that the financial advisors opinions do not reflect changes in circumstances after the date of such opinions.
• The document does not provide specific details on how the merger compares to industry standards in terms of valuation multiples or deal structures.
• It mentions that the financial advisors opinions do not reflect changes in circumstances after the date of such opinions.

Management Changes

Stakeholder Impact

• Shareholders of both companies will be impacted by the change in ownership structure and potential value creation.
• Employees may be affected by potential integration efforts and changes in roles or responsibilities.
• Customers and patients may benefit from the development of new and improved therapies.

Next Steps

• Alumis and ACELYRIN stockholders will vote on the merger-related proposals at their respective special meetings on May 13, 2025.
• The companies will work to satisfy the remaining closing conditions and obtain regulatory approvals.
• The combined company will integrate the two businesses and focus on advancing the pipeline.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stock issuance, biopharmaceutical, stockholders, agreement, TYK2, clinical trials, pipeline